Health Enhancement Products, Inc. Enters Into Collaborative Agreement With Global Animal Health Company to Accelerate Bovine ...
27 December 2013 - 12:30AM
Marketwired
Health Enhancement Products, Inc. Enters Into Collaborative
Agreement With Global Animal Health Company to Accelerate Bovine
Mastitis Product
KEEGO HARBOR, MI--(Marketwired - Dec 26, 2013) - Health
Enhancement Products, Inc. (OTCQB: HEPI) has entered into a
collaborative/option agreement with a global animal health company,
whose name is being withheld for competitive considerations and
intellectual property protection for both parties.
The terms of the agreement will allow Health Enhancement
Products to move forward with validation and product development in
direct collaboration with scientists from the animal health
company. At pre-determined intervals of 90 days each for an
evaluation period and a negotiation period which may culminate in a
final licensing arrangement, additional opportunities to further
disclose aspects of the agreement may occur.
The agreement provides for a licensing option covering bovine
applications across a range of modalities, and includes the
Company's natural compound, the proprietary refined algal extract
and the synthetic molecules developed by Health Enhancement.
Additional details may be released over the next few weeks.
Recently, the Company released notice of its early success in
addressing mycoplasma bovis, a contagious pathogen
responsible for a significant number of infections that result in
bovine mastitis, and for which there exist limited treatment
options.
About Health Enhancement Products, Inc.
Health Enhancement Products, Inc. (OTCQB: HEPI) is a health and
wellness company engaged in the development of natural bioactive
compounds for use as dietary supplements and food ingredients, as
well as biologics for medicinal and pharmaceutical applications in
humans and animals. The Company's scientific efforts are focused on
the metabolic aspects of oxidation and inflammation, with a
parallel program to validate and license products for healthy
cholesterol balance.
Safe Harbor Statement
Except for any historical information, the matters discussed in
this press release contain forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934. These forward-looking
statements involve risks and uncertainties. A number of factors
could cause actual results to differ from those indicated in the
forward-looking statements, including the timing of completion of a
trial, actual future clinical trial results being different than
the results the company has obtained to date, and the company's
ability to secure funding. Such statements are subject to a number
of assumptions, risks and uncertainties. Readers are cautioned that
such statements are not guarantees of future performance and those
actual results or developments may differ materially from those set
forth in the forward-looking statements. The company undertakes no
obligation to publicly update or revise forward-looking statements,
whether as a result of new information or otherwise.
Zivo Bioscience (QB) (USOTC:ZIVO)
Historical Stock Chart
From Apr 2024 to May 2024
Zivo Bioscience (QB) (USOTC:ZIVO)
Historical Stock Chart
From May 2023 to May 2024